Anticorps Monoclonal anti-AGO2

• Phare
• Validé par KD/KO

AGO2 Monoclonal Antibody for IHC, WB, ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Humain, rat, souris

Applications

WB, RIP, IP, IHC, ELISA

Conjugaison

Non conjugué

Publications

24

CloneNo.

1G2H12

N° de cat : 67934-1-Ig

Synonymes

AGO2, Argonaute2, eIF 2C 2, eIF2C 2, EIF2C2, hAgo2, PAZ Piwi domain protein, PPD, Protein argonaute 2, Protein slicer, Q10

---

Galerie de données de validation

• 

  WB analysis using 67934-1-Ig

  Various lysates were subjected to SDS PAGE followed by western blot with 67934-1-Ig (AGO2 antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours. The membrane was stripped and reblotted with HRP-conjugated Beta Actin Monoclonal antibody (HRP-66009) as loading control.

• 

  WB analysis using 67934-1-Ig

  Various lysates were subjected to SDS PAGE followed by western blot with 67934-1-Ig (AGO2 antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours. The membrane was stripped and reblotted with HRP-conjugated Beta Actin Monoclonal antibody (HRP-66009) as loading control.

• 

  WB analysis of HepG2 using 67934-1-Ig

  WB result of AGO2 antibody (67934-1-Ig; 1:1000; incubated at room temperature for 1.5 hours) with sh-Control and sh-AGO2 transfected HepG2 cells.

• 

  WB analysis of 4T1 using 67934-1-Ig

  4T1 cells were subjected to SDS PAGE followed by western blot with 67934-1-Ig (AGO2 antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human urothelial carcinoma using 67934-1-Ig

  Immunohistochemical analysis of paraffin-embedded human urothelial carcinoma tissue slide using 67934-1-Ig (AGO2 antibody) at dilution of 1:400 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human pancreas cancer using 67934-1-Ig

  Immunohistochemical analysis of paraffin-embedded human pancreas cancer tissue slide using 67934-1-Ig (AGO2 antibody) at dilution of 1:400 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Applications testées

• Résultats positifs en WB: cellules LNCaP, cellules 4T1, cellules HEK-293, cellules HeLa, cellules HepG2, cellules HSC-T6, cellules K-562, cellules MCF-7
• Résultats positifs en IHC: tissu de cancer du pancréas humain, tissu de carcinome urothélial humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:1000-1:5000
• Immunohistochimie (IHC): IHC : 1:200-1:800

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• WB: See 4 publications below
• IP: See 3 publications below
• RIP: See 18 publications below

Informations sur le produit

67934-1-Ig cible AGO2 dans les applications de WB, RIP, IP, IHC, ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Réactivité citée: Humain, souris
• Hôte / Isotype: Mouse / IgG1
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: AGO2 Protéine recombinante Ag27772
• Nom complet: eukaryotic translation initiation factor 2C, 2
• Masse moléculaire calculée: 97 kDa
• Poids moléculaire observé: 90 kDa
• Numéro d’acquisition GenBank: BC007633
• Symbole du gène: EIF2C2
• Identification du gène (NCBI): 27161
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par protéine A
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

EIF2C2, also named as AGO2, belongs to the argonaute family and Ago subfamily. It is required for RNA-mediated gene silencing (RNAi) by the RNA-induced silencing complex (RISC). The 'minimal RISC' appears to include EIF2C2/AGO2 bound to a short guide RNA such as a microRNA (miRNA) or short interfering RNA (siRNA). EIF2C2 may inhibit translation initiation by binding to the 7-methylguanosine cap, thereby preventing the recruitment of the translation initiation factor eIF4-E. It also inhibit translation initiation via interaction with EIF6, which itself binds to the 60S ribosomal subunit and prevents its association with the 40S ribosomal subunit. EIF2C2 can also upregulate the translation of specific mRNAs under certain growth conditions.

Publications

Species	Application	Title
human	WB	Clin Transl Med; LncRNA BC promotes lung adenocarcinoma progression by modulating IMPAD1 alternative splicing; Authors - Qi Wen Chen
mouse	RIP	Environ Health Perspect; Evaluation of Early Biomarkers of Atherosclerosis Associated with Polychlorinated Biphenyl Exposure: An in Vitro and in Vivo Study.; Authors - Bingwei Yang
human	WB,IP	J Med Chem; Discovery of a Novel Small-Molecule Inhibitor Disrupting TRBP-Dicer Interaction against Hepatocellular Carcinoma via the Modulation of microRNA Biogenesis.; Authors - Ting Peng
mouse	RIP	Life Sci; LncRNA PEG11as aggravates cerebral ischemia/reperfusion injury after ischemic stroke through miR-342-5p/PFN1 axis; Authors - Zhijun Yu
mouse	WB	J Genet Genomics; LSM14B coordinates protein component expression in the P-body and controls oocyte maturation; Authors - Huiru Zhang
human	RIP	Cancer Sci; ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells; Authors - Lifeng Zhao